Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.61 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.57 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.54 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.54 |
| ▸ | IDO1 | P14902 | 2/20 | 0.51 |
| ▸ | AGXT | P21549 | 2/20 | 0.51 |
| ▸ | CMA1 | P23946 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.51 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.51 |
| ▸ | DAO | P14920 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10636948 | 0.90 | CHRM2 (0.58) | TAAR1CHRM2CHRM1CHRM3SIGMAR1 | |
| SCHEMBL910726 | 0.83 | CHRM2 (0.55) | TAAR1CHRM2CHRM1CHRM3 | |
| SCHEMBL723511 | 0.82 | TAAR1 (0.77) | TAAR1CHRM2CHRM1CHRM3SIGMAR1 | |
| SCHEMBL30080050 | 0.82 | TAAR1 (0.77) | TAAR1CHRM2CHRM1CHRM3SIGMAR1 | |
| SCHEMBL1233549 | 0.82 | MEN1 (0.66) | TAAR1CHRM2CHRM1CHRM3SIGMAR1 | |
| SCHEMBL5703462 | 0.82 | TAAR1 (0.61) | TAAR1CHRM2CHRM1CHRM3SIGMAR1 | |
| SCHEMBL362937 | 0.81 | TAAR1 (0.59) | TAAR1CHRM2CHRM1CHRM3SIGMAR1 | |
| SCHEMBL5542339 | 0.81 | CYP19A1 (0.48) | DAO | |
| SCHEMBL9825782 | 0.81 | KDM4E (0.59) | — | |
| SCHEMBL910492 | 0.80 | KMT2A (0.49) | CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113024360-B | Synthesis method of m-methoxy benzyl alcohol | 国药集团化学试剂有限公司 | 2022-07-08 | — | — | CN | claimed |
| CN-113024360-A | Synthesis method of m-methoxy benzyl alcohol | 国药集团化学试剂有限公司 | 2021-06-25 | — | — | CN | claimed |
| US-10787484-B2 | Compositions and methods for treating cardiovascular disease | GENENTECH, INC. (US) | 2020-09-29 | — | — | US | claimed |
| US-20190177366-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE | GENENTECH, INC. (US) | 2019-06-13 | — | — | US | claimed |
| US-20040186151-A1 | Substituted azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. | 2004-09-23 | — | — | US | claimed |
| WO-2004071448-A2 | SUBSTITUTED AZOLE DERIVATIVES AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | TRANSTECH PHARMA INC. (US) | 2004-08-26 | — | — | WO | claimed |
| CN-1050996-C | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides | PRO NEURON INC (US) | 2000-04-05 | — | — | CN | claimed |
| CN-1192149-A | Methods of reducing toxicity of chemotherapeutic and antiviral agents with acylated pyrimidine nucleosides | PRO NEURON INC (US) | 1998-09-02 | — | — | CN | claimed |
| CN-1071577-A | Handle the toxicity of chemotherapy reagent and Anti-virus agent with acylated pyrimidine nucleosides | PRO NEURON INC (US) | 1993-05-05 | — | — | CN | claimed |
| CN-114173780-A | Compounds for reducing the deleterious activity of genes containing extended nucleotide repeats | 小利兰·斯坦福大学托管委员会 | 2022-03-11 | — | — | CN | disclosed |
| US-11034725-B2 | Compositions and methods for treating cardiovascular disease | GENENTECH, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-10787484-B2 | Compositions and methods for treating cardiovascular disease | GENENTECH, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| US-20200283478-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE | GENENTECH, INC. (US) | 2020-09-10 | — | — | US | disclosed |
| CN-110996942-A | Compounds for reducing the deleterious activity of genes containing extended nucleotide repeats | 小利兰.斯坦福大学托管委员会 | 2020-04-10 | — | — | CN | disclosed |
| CN-1071577-A | Handle the toxicity of chemotherapy reagent and Anti-virus agent with acylated pyrimidine nucleosides | PRO NEURON INC (US) | 1993-05-05 | — | — | CN | disclosed |
| US-4487772-A | CARDIOTONIC AGENTS | OTSUKA PHARMACEUTICAL CO. LTD. (JP) | 1984-12-11 | — | — | US | disclosed |
| US-4468402-A | Carbostyril derivatives, process for producing the same and cardiotonic compositions containing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-08-28 | — | — | US | disclosed |
| US-4454130-A | CARDIOTONIC, HYPOTENSIVE AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-06-12 | — | — | US | disclosed |
| US-4438277-A | Hydronaphthalene derivatives | SANKYO COMPANY, LIMITED (JP) | 1984-03-20 | — | — | US | disclosed |
| US-4361515-A | Antihyperlipemic dihydro-ML-236B derivatives, their preparation and use | SANKYO COMPANY, LIMITED (JP) | 1982-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200283478-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE | PCSK9, PCSK7, PCSK6 | TAAR1 4623/4885CHRM2 4639/4885CHRM1 4746/4885 |
| US-11034725-B2 | Compositions and methods for treating cardiovascular disease | PCSK9, PCSK7, PCSK6 | TAAR1 4623/4885CHRM2 4639/4885CHRM1 4746/4885 |
| US-10787484-B2 | Compositions and methods for treating cardiovascular disease | PCSK9, PCSK7, PCSK6 | TAAR1 4623/4885CHRM2 4639/4885CHRM1 4746/4885 |
| US-20190177366-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE | PCSK9, PCSK7, PCSK6 | TAAR1 4623/4885CHRM2 4639/4885CHRM1 4746/4885 |
| US-20040186151-A1 | Substituted azole derivatives as therapeutic agents | PTPRS, PTPRO, PTPRJ | TAAR1 2996/4885CHRM2 4066/4885CHRM1 4164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.